Previous 10 | Next 10 |
2024-02-05 10:24:24 ET More on MorphoSys MorphoSys: Positive Pelabresib Data Finally Unlocking Upside MorphoSys: A Buying Opportunity Following Mixed Phase 3 Results In Myelofibrosis MorphoSys: Buying Constellation Was A Desperate Measure MorphoSys expects 20...
2024-01-30 08:45:08 ET Agilent Technologies ( NYSE: A ) and Incyte ( NASDAQ: INCY ) have collaborated to develop advanced companion diagnostics in hematology and oncology.... Read the full article on Seeking Alpha For further details see: Agilent, Incyte ...
2024-01-24 14:39:16 ET More on S&P 500 Index: Bullard Says A March Rate Cut Looks Prudent PBOC Cuts Reserve Requirements, But USD Pullback May Offer New Buying Opportunity In North America SPY: Black Swan Hiding In Plain Sight Walmart is the least shorted...
2024-01-23 17:10:35 ET Summary Merus N.V. shares have remained strong despite negative safety news about its MCLA-129 program, as attention shifts to promising candidates petosemtamab and zenocutuzumab. Petosemtamab shows solid overall response rates for head and neck cancer, whil...
Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2023 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 13, 2024. The schedule for the press release and conference call/webcast is as follows: Q4 & YE 2023 Pr...
2024-01-11 07:53:52 ET More on Aclaris Therapeutics Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report Aclaris downgraded at Jefferies despite mid-stage win for eczema therapy Aclaris posts topline data from mid-stage trial for eczema therapy ...
Presentation underscores potential of several high-impact launches across Oncology and Inflammation & Autoimmunity to drive sustainable long-term growth Company announces new positive topline results from Phase 2 trial evaluating ruxolitinib cream (Opzelura ® ) in adults with...
2024-01-05 14:30:17 ET More on the markets SPY And QQQ: Fundamentals Remain Strong, Buying The Dip Verily Volatility: SPY Puts Are Cheap And The Market Is Selling Off The Market Looks Poised To Make New Highs In 2024 ETFs attract $597B in 2023 marking the fou...
2023-12-27 12:29:36 ET More on AbbVie, Johnson & Johnson, etc. Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) AbbVie Vs. GSK: Dual Dominance In Pharma ...
2023-12-26 11:15:43 ET Summary Syndax Pharmaceuticals, Inc. has experienced a roller coaster ride in the stock market, but is currently up 80% from its lows in October. The company has two candidates in development that are poised to garner FDA approval in 2024 and also just fille...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 11:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 06:15:05 ET BMO Capital analyst issues UNDERPERFORM recommendation for INCY on July 2, 2024 04:26AM ET. The previous analyst recommendation was Market Perform. INCY was trading at $60.87 at issue of the analyst recommendation. The overall analyst consensus : B...